Trials / Completed
CompletedNCT00131118
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
Efficacy and Safety of Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 127 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 1 Year – 17 Years
- Healthy volunteers
- —
Summary
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zoledronic Acid |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2005-08-17
- Last updated
- 2017-06-01
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00131118. Inclusion in this directory is not an endorsement.